Alkem Laboratories' Bioequivalence Center clears US FDA inspection

Alkem Laboratories' Bioequivalence Center clears US FDA inspection.

announced a US FDA BIMO inspection at its Taloja facility from March 10-13, 2025, with no Form 483 issued. The company reported a 5% YoY increase in net profit to ₹626 crore, with revenue rising 1.5% to ₹3,374 crore and EBITDA up 7.4% to ₹759 crore. US sales contributed 19.1% of total sales.